FIGURE 5 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

<p>Cetuximab treatment benefits Hypoxia subgroup. <b>A,</b> Heatmap of gene expression data from pre- and post-cetuximab (CTX) treated patient samples. RNA expression data (GSE109756) was z-normalized, each row represents a single gene in the hypoxia-immune signature gene list, each column represents a patient sample. Hierarchical clustering was performed as detailed in Materials and Methods. Samples were reordered according to its molecular subgroup: Immune (blue), mixture (black), and Hypoxia (red) with pre-cetuximab treated samples labeled BC and post-cetuximab labeled OC. TIMEx scores for the Hypoxia gene signature among the 15 patients classified into the three subgroups (<b>B</b>) and GSEA comparing gene expression changes in the pre- and post-cetuximab data using CIBERSORT gene sets: higher in post-cetuximab (red) and higher in pre-ceuximab (blue) (<b>C</b>).</p>